Thelansis

 Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome (HPS), is a rare, life-threatening hematologic disorder manifested by clinical findings of extreme inflammation and unregulated immune activation. In both its congenital (primary) and adult (secondary) forms, an underdiagnosed syndrome is caused by the overwhelming dysregulation of the immune system, resulting in end organ damage or even death if untreated. It is described as a hyperinflammatory reaction with uncontrolled, persistent activation of lymphocytes and macrophages engulfing hematopoietic cells, creating a vicious cycle of a cytokine storm. The diagnostic criteria of HLH involve a molecular diagnosis or meeting five of the eight criteria, including fever, splenomegaly, bicytopenia, hypertriglyceridemia and hypofibrinogenemia, hemophagocytosis in the bone marrow, low or absent NK cell activity, elevated ferritin levels and elevated soluble CD25 levels. Hyperferritinemia and elevated soluble CD25 a

 Hemophagocytic lymphohistiocytosis (HLH) is a condition in which the body produces an abnormally large number of activated immune cells (macrophages and lymphocytes). There are inherited, and non-inherited (acquired) causes of hemophagocytic lymphohistiocytosis (HLH). The acquired causes of HLH include infection, medications that suppress the immune system, autoimmune diseases, immunodeficiencies, certain types of cancer, and/or metabolic diseases. When HLH results from an inappropriate immune response to the Epstein-Barr virus or another viral illness, it may be due to a separate genetic condition called X-linked lymphoproliferative disease (XLP). XLP is caused by a mutation in the SH2D1A or XIAP gene and is inherited in an X-linked manner. Thelansis’s “Hemophagocytic Lymphohistiocytosis (HLH) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, com